drugset / Trial / NCT01024894
Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to evaluate the safety of biological active dose of a new experimental drug, IL-7, in combination with standard bi-therapy in Asiatic patients with Hepatitis C chronic infection identified as non responders to the standard bi-therapy alone.
Timeline
- Start
- 2009-01
- Primary completion
- 2012-11
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interleukin-7 | Protein / enzyme biologic | 3 ug/kg | Subcutaneous |
| Subject | Interleukin-7 | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |
| Subject | Interleukin-7 | Protein / enzyme biologic | 20 ug/kg | Subcutaneous |